Clinical trial · Observational
A Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy
Construction of a Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy
NCT07119190CI-TRIAL-00093516not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to develop and refine an integrated minimally invasive care pathway for resectable lung cancer in the immunotherapy era, establishing a novel precision perioperative immunotherapy paradigm encompassing original techniques and clinical applications.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Prospective cohort
- description
- Non-small cell Lung cancer patients receiving neoadjuvant immunotherapy and surgery
Primary outcomes (1)
- measure
- Pathological Complete Response (pCR)
- timeFrame
- At surgery (typically 3-6 months post-treatment initiation)
- description
- Pathologic Complete Response (pCR) is defined as the absence of residual tumor in both the primary lung tumor site and all sampled regional lymph nodes after neoadjuvant immunotherapy, confirmed through systematic pathological examination of the surgical specimen.
Secondary outcomes (8)
- measure
- Major Pathological Response (MPR)
- timeFrame
- At surgery (typically 3-6 months post-treatment initiation)
- description
- Major Pathologic Response (MPR) is defined as the presence of ≤10% residual viable tumor cells in both the primary lung tumor site and sampled regional lymph nodes after neoadjuvant immunotherapy, confirmed through systematic pathological examination of the surgical specimen.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years old; 2. NSCLC patients underwent radical surgical resection; 3. Adequate clinical-pathologic data, imaging data and follow-up data obtainable for multi-omics analysis; 4. Scheduled for or currently receiving neoadjuvant/perioperative immunotherapy. Exclusion Criteria: 1. Histology of other malignant tumors, including concurrent malignant tumors of other organ systems; 2. Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC); 3. Pregnancy or lactation; 4. Insufficient sample quality; 5. Severe organ dysfunction (e.g. cardiac or renal insufficiency); 6. Other judgments by the Investigator that the patient should not participate in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.